Antibody-drug conjugates in hematologic malignancies
Krish Patel1, Stephen A Strickland1, Hans C Lee1
1Sarah Cannon Research Institute, Nashville, Tennessee, USA.
Abstract:
Antibody-drug conjugates (ADCs) represent an important therapeutic modality for the treatment of various hematologic malignancies. These include gemtuzumab ozogamicin and inotuzumab ozagamicin for acute leukemias; brentuximab vedotin, polatuzumab vedotin, and loncastuximab tesirine for lymphoid malignancies; and belantamab mafadotin for multiple myeloma. Although ADCs do provide an effective off-the-shelf approach to selectively deliver cytotoxic agents by targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen target, linker, or payload that have limited their development. In this review, the clinical development and current role of ADCs in the therapeutic landscape of hematologic malignancies are discussed.
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

